Abstract
This study investigates the impact of 450191-S, a novel triazolyl benzophenone derivative sleep inducer, on hepatic drug-metabolizing enzymes in rats. Comparisons with nitrazepam and phenobarbital revealed that 450191-S induces Cytochrome P-450-dependent enzymes at high doses (150-200 mg/kg) after 3-5 days of administration. This induction is reversible upon drug withdrawal and follows a phenobarbital-type pattern, though its potency is similar to nitrazepam and significantly weaker than phenobarbital.
Introduction
When a new medication is developed, understanding its interaction with the liver's metabolic pathways is crucial. The Cytochrome P-450 (CYP) enzyme family is responsible for breaking down most drugs. Some substances, known as "inducers," can increase the production of these enzymes, potentially leading to drug-drug interactions where co-administered medications are cleared too rapidly. This study focuses on 450191-S, a novel sleep inducer.
Methods
The researchers administered 450191-S orally to rats and mice at various doses (50 to 600 mg/kg/day) for periods ranging from 1 to 14 days. They used several key techniques to measure the liver's response:
- Enzyme Activity Assays: Measuring the "O-dealkylation" of 7-alkoxycoumarins (methoxy, ethoxy, and propoxy) to identify which specific P-450 enzyme sub-families are active.
- Protein Quantification: Direct measurement of Cytochrome P-450 and cytochrome $b_5$ levels in liver microsomes.
- Functional Testing: Using pentobarbital-induced sleeping time as a bio-assay for metabolic clearance rates.
Results
The study identified a clear "Phenobarbital-type" (PB-type) induction signature. Unlike "MC-type" inducers that target specific pathways, 450191-S increased the metabolism across all three alkoxycoumarin probes.
Induction was dose- and time-dependent, requiring at least 150–200 mg/kg for 3–5 days to show significant effects. Importantly, this effect was fully reversible within 3–5 days of drug cessation. Functional tests confirmed these findings: rats pre-treated with 450191-S woke up significantly faster from pentobarbital-induced sleep, proving the enzymes were not just present, but actively clearing drugs faster.
In terms of relative potency, 450191-S showed inducing activity comparable to nitrazepam but significantly weaker than phenobarbital. Furthermore, unlike phenobarbital, 450191-S did not cause significant liver hypertrophy (enlargement) at the doses tested in rats.
Discussion and Limitations
While the PB-type induction pattern is evident, the specific P-450 isozymes involved require further molecular characterization. Species sensitivity varied, with mice showing induction at lower doses (50 mg/kg) than rats. These differences necessitate caution when extrapolating these findings to human clinical settings, suggesting a need for future studies in human liver models to better predict clinical drug-drug interaction risks.
Summary updated